|
Study: 30% Decline in eGFR Over 2 Years Strongly Predicts ESRD - Renal and Urology News |
 |
 |
July 20, 2015
Baseline eGFR, higher phosphorus, proteinuria, and male gender, also are associated with an elevated risk of end-stage renal disease in patients with chronic kidney disease.
The future incidence of end-stage renal disease (ESRD)among patients with chronic kidney disease is best predicted by a 30% decline in estimated glomerular filtration rate (eGFR) over 2 years, new findings suggest.
In a study of 701 patients with chronic kidney disease (CKD), a team led by Shunya Uchida, MD, of Tianjin First Central Hospital in Tianjin, China, found that this magnitude of decline was associated with a significant 31.6 times increased risk of ESRD compared with a 0% to 10% decline over 2 years (reference), according to an online report in PLOS One (10;e0132927).
Baseline eGFR and proteinuria were the most important risk factors for predicting ESRD. Serum phosphorus levels and male sex also predicted an elevated risk of ESRD. Each 1 mg/dL increment in serum phosphorus during follow-up was associated with a 2.7 times increased risk of ESRD. Male sex was associated with a significant 2.6 times increased risk compared with female sex.
Baseline eGFR and proteinuria were the most important risk factors for predicting ESRD, according to the investigators. Results showed that higher albumin and hemoglobin levels were associated with a lower risk of ESRD.
Of the 701 subjects, 83 progressed to ESRD during a mean follow-up of 4.5 years (maximum 6 years).
The new findings corroborate those of a study by Josef Coresh, MD, and colleagues, who reported in the Journal of the American Medical Association (2014;311:2518-2531) that a 30% decline in eGFR over 2 years showed that highest percentage of population attributable risk.
|
|
Study: 30% Decline in eGFR Over 2 Years Strongly Predicts ESRD - Renal and ... - Renal and Urology News |
|
|
July 20, 2015
Baseline eGFR, higher phosphorus, proteinuria, and male gender, also are associated with an elevated risk of end-stage renal disease in patients with chronic kidney disease.
The future incidence of end-stage renal disease (ESRD)among patients with chronic kidney disease is best predicted by a 30% decline in estimated glomerular filtration rate (eGFR) over 2 years, new findings suggest.
In a study of 701 patients with chronic kidney disease (CKD), a team led by Shunya Uchida, MD, of Tianjin First Central Hospital in Tianjin, China, found that this magnitude of decline was associated with a significant 31.6 times increased risk of ESRD compared with a 0% to 10% decline over 2 years (reference), according to an online report in PLOS One (10;e0132927).
Baseline eGFR and proteinuria were the most important risk factors for predicting ESRD. Serum phosphorus levels and male sex also predicted an elevated risk of ESRD. Each 1 mg/dL increment in serum phosphorus during follow-up was associated with a 2.7 times increased risk of ESRD. Male sex was associated with a significant 2.6 times increased risk compared with female sex.
Baseline eGFR and proteinuria were the most important risk factors for predicting ESRD, according to the investigators. Results showed that higher albumin and hemoglobin levels were associated with a lower risk of ESRD.
Of the 701 subjects, 83 progressed to ESRD during a mean follow-up of 4.5 years (maximum 6 years).
The new findings corroborate with those of a study by Josef Coresh, MD, and colleagues, who reported in the Journal of the American Medical Association (2014;311:2518-2531) that a 30% decline in eGFR over 2 years showed that highest percentage of population attributable risk.
|
|
|
Nivolumab Superior to Everolimus for Previously-treated Renal Cell Carcinoma ... - Cancer Therapy Advisor |
|
|
July 20, 2015
Bristol-Myers Squibb has announced the early closure of its phase 3 CheckMate-025 trial evaluating nivolumab (Opdivo).
Bristol-Myers Squibb has announced the early closure of its phase 3 CheckMate-025 trial evaluating nivolumab (Opdivo) compared with everolimus for the treatment of previously-treated patients with advanced or metastatic renal cell carcinoma.
The study was stopped early because an independent Data Monitoring Committee assessment found that nivolumab is superior to everolimus in this patient population.
“The results of CheckMate-025 mark the first time an Immuno-Oncology agent has demonstrated a survival advantage in advanced renal cell carcinoma, a patient group that currently has limited treatment options,” said Michael Giordano, senior vice president, Head of Development, Oncology, Bristol-Myers Squibb.
“Through our Opdivo clinical development program, we aim to redefine treatment expectations for patients with advanced RCC by providing improved survival.”
For the open-label trial, 821 previously-treated patients with advanced or metastatic clear-cell renal cell carcinoma were randomly assigned to receive either everolimus 10 mg orally daily or nivolumab 3 mg/kg intravenously until unacceptable toxicity or disease progression. The primary endpoint was overall survival with objective response rate and progression-free survival as secondary endpoints.
Eligible patients receiving everolimus will be given the opportunity to continue the current treatment or initiate treatment with nivolumab as part of an open-label extension.
RELATED: Deferred Systemic Therapy Reasonable for Selected Renal Cell Carcinoma Patients
Opdivo is already U.S. Food and Drug Administration (FDA)-approved for the treatment of certain patients with unresectable or metastatic melanoma and metastatic squamous non-small cell lung cancer.
Clear-cell renal cell carcinoma is the most common type of renal cell carcinoma and the most prevalent form of kidney cancer among adults.
Reference:
- CheckMate-025, a Pivotal Phase III Opdivo (nivolumab) Renal Cell Cancer Trial, Stopped Early [news release]. Princeton, NJ: Bristol-Myers Squibb. July 20, 2015. http://news.bms.com/press-release/checkmate-025-pivotal-phase-iii-opdivo-nivolumab-renal-cell-cancer-trial-stopped-early. Accessed July 20, 2015.
|
|
FMS Stock | 3 Health Services Stocks Nudging The Industry Higher - TheStreet - TheStreet.com |
|
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
